OncoMatch/Clinical Trials/NCT05218889
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
Is NCT05218889 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including surufatinib + camrelizumab + nab-paclitaxel + S-1 and nab-paclitaxel + gemcitabine for pancreatic cancer.
Treatment: surufatinib + camrelizumab + nab-paclitaxel + S-1 · nab-paclitaxel + gemcitabine — This study is designed to explore the efficacy and safety of surufatinib combined with camrelizumab and AS (nab-paclitaxel and S-1) as first-line treatment compared with AG (nab-paclitaxel and gemcitabine) in unresectable advanced or metastatic pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage III, IV
unresectable, locally advanced, or metastatic pancreatic ductal adenocarcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: VEGFR inhibitor
Previously received treatment with VEGFR inhibitors
Cannot have received: immune checkpoint inhibitor
previously used ICI treatment
Cannot have received: systemic anti-tumor treatment
Have received other systemic anti-tumor treatments within 4 weeks prior to enrollment, including chemotherapy, signal transduction inhibitors, hormone therapy, and immunotherapy
Cannot have received: local anti-tumor treatment
Have received local anti-tumor treatments within 4 weeks prior to enrollment, such as hepatic arterial interventional embolism, cryoablation or radiofrequency ablation of metastases to liver
Cannot have received: brachytherapy
Brachytherapy (radioactive seed implantation) within 60 days prior to enrollment
Cannot have received: major surgery
Undergone major surgery within 60 days prior to enrollment or the surgical incision has not completely healed
Lab requirements
Blood counts
Absolute neutrophil count ≥1.5×10^9/L; Platelets ≥100×10^9/L; Haemoglobin ≥90 g/L
Kidney function
Serum creatinine < 1.5 × ULN; Endogenous creatinine clearance ≥50 mL/min
Liver function
Total bilirubin < 1.5 × ULN; ALT and/or AST < 1.5 × ULN (< 3 × ULN for patients with metastases to liver)
Cardiac function
LVEF (left ventricular ejection fraction) <50% excluded; NYHA classification > Class II excluded; acute myocardial infarction within 6 months, severe/unstable angina, coronary artery bypass surgery, ventricular arrhythmia requiring drug therapy, cardiac failure congestive
The functions of vital organs meet the following requirements... (see above for details); Clinically significant cardiovascular disorders, including but not limited to acute myocardial infarction within 6 months prior to enrollment, severe/unstable angina pectoris, or coronary artery bypass surgery; cardiac failure congestive with NYHA classification > Class II; ventricular arrhythmia requiring drug therapy; LVEF (left ventricular ejection fraction) <50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify